Handelsavisen
prelaunch
Companies ›Healthcare ›ELTX
EL
ELTX — Nasdaq Pharmaceuticals

Elicio Therapeutics, Inc.

$2,85
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
51,9M USD
P/E
—
EV / Rev
—
Div yield
—
Op margin
—
ROE
822,8 %
Net margin
—
Debt / equity
-6,59
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$5,14
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About

Elicio Therapeutics, Inc. is classified under Healthcare / Pharmaceuticals and appears not currently profitable on the latest normalized snapshot.

Business. Elicio Therapeutics, Inc. (ELTX) is a pharmaceutical company operating within the Healthcare sector. The firm is headquartered in the United States and is primarily listed on the Nasdaq stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.

Classification98 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
Industry groupPharmaceuticals
Generated · rules-based
Sell-side consensus
BUY4 analysts
3 buy1 hold0 sell
Avg 12m price target20,00

Analyst recommendations

4 analysts · consensus Buy
Buy3
Hold1
Sell0
12-month price target
20,00
Consensus of sell-side coverage.
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
4 analysts · indicative
Ownership→
Geode Capital Management, L.L.C.
largest disclosed fund holder
Profitability→
822,8 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning ELTX.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to ELTX. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Elicio Therapeutics, Inc. (ELTX) is a pharmaceutical company operating within the Healthcare sector. The firm is headquartered in the United States and is primarily listed on the Nasdaq stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.

    Classification98 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    Industry groupPharmaceuticals
    AI synthesis
    GENERATED

    Elicio Therapeutics, Inc. (ELTX) is currently classified as Pharmaceuticals within Pharmaceuticals (Healthcare). Classification confidence: 0.98 (rule-based classification). Capital structure on the latest snapshot: total assets 22,689,000 USD, total equity -1,437,000, short-term debt 0, long-term debt 9,475,000. Net cash position is approximately 5,473,000 USD. Self-calculated market cap is 58,641,819 USD (market_price × shares_outstanding_diluted). Profitability profile: revenue 0, gross profit 0, operating income -10,602,000, net income -11,823,000. Return on equity ~822.8%. Return on assets ~-52.1%. Operating-cash-flow to net-income ratio is 0.98. Risk profile from automated assessment: liquidity risk high, dilution risk medium. Flags: Filings reference going-concern or substantial-doubt language.; Source documents mention dilution or offering risk.. Recent news context: [TRIGGER] 8-K: 8-K (sec_8k_material) on ELTX — filing_type=8-K; max_severity=high; ignored_items=['8.01', '9.01']; material_items=['1.01']; all_items_found=['1.01', '8.01', '9.01']; severity_per_code={'1.01': 'high'}; contributing_watchers=sec_8k_material (source=sec_8k_material; url=0001104659-26-080058). Additional context: 8-K: filing_type=8-K; max_severity=high; ignored_items=['8.01', '9.01']; material_items=['1.01']; all_items_found=['1.01', '8.01', '9.01']; severity_per_code={'1.01': 'high'}; contributing_watchers=sec_8k_material.

    Key takeaways
    • Return on equity is about 822.8%.
    • Debt to equity is about -6.59x.
    • [TRIGGER] 8-K: 8-K (sec_8k_material) on ELTX — filing_type=8-K; max_severity=high; ignored_items=['8.01', '9.01']; material_items=['1.01']; all_items_found=['1.01', '8.01', '9.01']; severity_per_code={'1.01': 'high'}; contributing_watchers=sec_8k_material (source=sec_8k_material; url=0001104659-26-080058)
    • eltx-20260331 March 31, 2026 2026 Q1 12-31 0001601485 False 0.1 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure eltx:agreement eltx:entity 0001601485 2026-01-01 2026-03-31 0001601485 2026-05-08 0001601485 2026-03-31 0001601485 2025-12-31 0001601485 2025-01-01 2025-03-31 0001601485 us-gaap:CommonStockMember 2025-12-31 0001601485 us-gaap:TreasuryStockCommonMember 2025-12-31 0001601485 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001601485 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-12-31 0001601485 us-gaap:RetainedEarningsMember 2025-12-31 0001601485 eltx:AtTheMarketEquityOfferingSalesAgreement2026Member 2026-01-01 2026-03-31 0001601485 eltx:AtTheMarketOfferingMember us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001601485 eltx:AtTheMarketOfferingMember us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0001601485 eltx:AtTheMarketOfferingMember 2026-01-01 2026-03-31 0001601485 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001601485 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0001601485 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-01-01 2026-03-31 0001601485 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0001601485 us-gaap:CommonStockMember 2026-03-31 0001601485 us-gaap:TreasuryStockCommonMember 2026-03-31 0001601485 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001601485 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-03-31 0001601485 us-gaap:RetainedEarningsMember 2026-03-31 0001601485 us-gaap:CommonStockMember 2024-12-31 0001601485 us-gaap:TreasuryStockCommonMember 2024-12-31 0001601485 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001601485 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001601485 us-gaap:RetainedEarningsMember 2024-12-31 0001601485 2024-12-31 0001601485 eltx:AtTheMarketOfferingMember 2025-01-01 2025-03-31 0001601485 eltx:AtTheMarketOfferingMember us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001601485 eltx:AtTheMarketOfferingMember us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001601485 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001601485 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001601485 eltx:ConversionOfConvertibleDebtMember us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001601485 eltx:ConversionOfConvertibleDebtMember us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001601485 eltx:ConversionOfConvertibleDebtMember 2025-01-01 2025-03-31 0001601485 eltx:JanuaryOfferingMember 2025-01-01 2025-03-31 0001601485 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0001601485 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001601485 us-gaap:CommonStockMember 2025-03-31 0001601485 us-gaap:TreasuryStockCommonMember 2025-03-31 0001601485 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001601485 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001601485 us-gaap:RetainedEarningsMember 2025-03-31 0001601485 2025-03-31 0001601485 eltx:A2024RegistrationStatementMember 2024-06-30 0001601485 eltx:AtTheMarketEquityOfferingSalesAgreement2024Member 2024-06-30 0001601485 eltx:AtTheMarketEquityOfferingSalesAgreement2024Member us-gaap:CommonStockMember 2025-01-01 2025-12-31 0001601485 eltx:AtTheMarketEquityOfferingSalesAgreement2024Member us-gaap:CommonStockMember 2025-12-31 0001601485 eltx:AtTheMarketEquityOfferingSalesAgreement2024Member us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001601485 eltx:AtTheMarketEquityOfferingSalesAgreement2024Member us-gaap:CommonStockMember 2026-03-31 0001601485 eltx:A2026RegistrationStatementMember 2026-02-28 0001601485 eltx:AtTheMarketEquityOfferingSalesAgreement2026Member 2026-02-28 0001601485 eltx:AtTheMarketEquityOfferingSalesAgreement2026Member us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001601485 eltx:AtTheMarketEquityOfferingSalesAgreement2026Member us-gaap:CommonStockMember 2026-03-31 0001601485 eltx:AtTheMarketEquityOfferingSalesAgreement2026Member 2026-02-28 2026-02-28 0001601485 eltx:AtTheMarketEquityOfferingSalesAgreement2026Member us-gaap:CommonStockMember 2026-02-01 2026-03-31 0001601485 eltx:AtTheMarketOfferingMember us-gaap:CommonStockMember 2026-03-31 0001601485 eltx:JanuaryCommonWarrantsMember 2025-01-01 2025-01-31 0001601485 eltx:JanuaryCommonWarrantsMember 2025-01-31 0001601485 eltx:JanuaryCommonWarrantsMember us-gaap:CommonStockMember 2025-01-31 0001601485 eltx:JanuaryCommonWarrantsMember us-gaap:CommonStockMember 2025-01-01 2025-01-31 0001601485 eltx:SeniorSecuredConvertiblePromissoryNoteMember 2025-06-30 0001601485 eltx:SeniorSecuredConvertiblePromissoryNoteMember 2025-09-30 0001601485 eltx:SeniorSecuredConvertiblePromissoryNoteMember 2025-06-01 2025-06-30 0001601485 eltx:AngionCommonStockMember 2023-06-01 2023-06-01 0001601485 us-gaap:FairValueInputsLevel1Member 2026-03-31 0001601485 us-gaap:FairValueInputsLevel2Member 2026-03-31 0001601485 us-gaap:FairValueInputsLevel3Member 2026-03-31 0001601485 us-gaap:FairValueInputsLevel1Member 2025-12-31 0001601485 us-gaap:FairValueInputsLevel2Member 2025-12-31 0001601485 us-gaap:FairValueInputsLevel3Member 2025-12-31 0001601485 eltx:WarrantLiabilityMember 2025-12-31 0001601485 eltx:WarrantLiabilityMember 2024-12-31 0001601485 eltx:WarrantLiabilityMember 2026-01-01 2026-03-31 0001601485 eltx:WarrantLiabilityMember 2025-01-01 2025-12-31 0001601485 eltx:WarrantLiabilityMember 2026-03-31 0001601485 eltx:MeasurementInputStrikePriceMember us-gaap:FairValueInputsLevel3Member 2026-03-31 0001601485 eltx:MeasurementInputStrikePriceMember us-gaap:FairValueInputsLevel3Member 2025-12-31 0001601485 us-gaap:MeasurementInputPriceVolatilityMember us-gaap:FairValueInputsLevel3Member 2026-03-31 0001601485 us-gaap:MeasurementInputPriceVolatilityMember us-gaap:FairValueInputsLevel3Member 2025-12-31 0001601485 us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:FairValueInputsLevel3Member 2026-03-31 0001601485 us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:FairValueInputsLevel3Member 2025-12-31 0001601485 us-gaap:MeasurementInputExpectedDividendRateMember us-gaap:FairValueInputsLevel3Member 2026-03-31 0001601485 us-gaap:MeasurementInputExpectedDividendRateMember us-gaap:FairValueInputsLevel3Member 2025-12-31 0001601485 eltx:JulyPublicOfferingMember 2024-07-01 2024-07-31 0001601485 eltx:JulyPreFundedWarrantsMember eltx:JulyPublicOfferingMember 2024-07-31 0001601485 eltx:JulyCommonWarrantsMember eltx:JulyPublicOfferingMember 2024-07-31 0001601485 eltx:JulySharesAndJulyCommonWarrantMember eltx:JulyPublicOfferingMember 2024-07-31 0001601485 eltx:JulyCommonWarrantsMember 2024-07-31 0001601485 eltx:JulyCommonWarrantsMember eltx:JulyPublicOfferingMember 2026-01-01 2026-03-31 0001601485 eltx:JulyCommonWarrantsMember eltx:JulyPublicOfferingMember 2025-01-01 2025-03-31 0001601485 us-gaap:EquipmentMember 2026-03-31 0001601485 us-gaap:EquipmentMember 2025-12-31 0001601485 us-gaap:FurnitureAndFixturesMember 2026-03-31 0001601485 us-gaap:FurnitureAndFixturesMember 2025-12-31 0001601485 us-gaap:LeaseholdImprovementsMember 2026-03-31 0001601485 us-gaap:LeaseholdImprovementsMember 2025-12-31 0001601485 eltx:ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept2022Member 2022-09-30 0001601485 eltx:ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept.2023Member 2023-09-30 0001601485 eltx:ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFAugust2024Member 2024-08-31 0001601485 eltx:ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept2022Member 2026-03-31 0001601485 eltx:ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept2022Member 2025-01-01 2025-03-31 0001601485 eltx:ResearchGrantAgreementWithTheGastroIntestinalResearchFoundationGIRFSept2022Member 2026-01-01 2026-03-31 0001601485 eltx:AtTheMarketEquityOfferingSalesAgreement2024Member us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001601485 eltx:AtTheMarketEquityOfferingSalesAgreement2024Member us-gaap:CommonStockMember 2025-03-31 0001601485 eltx:JanuaryPublicOfferingMember us-gaap:CommonStockMember 2025-01-01 2025-01-31 0001601485 eltx:January2025CommonWarrantsMember 2025-01-31 0001601485 eltx:JanuaryCommonWarrantsMember eltx:JanuaryPublicOfferingMember 2025-01-31 0001601485 us-gaap:CommonStockMember 2025-01-01 2025-01-31 0001601485 eltx:SeniorSecuredConvertiblePromissoryNoteMember us-gaap:ConvertibleDebtMember 2024-08-31 0001601485 us-gaap:ConvertibleDebtMember 2024-08-01 2024-08-31 0001601485 eltx:PreFundedWarrantMember us-gaap:CommonStockMember 2025-03-31 0001601485 eltx:PreFundedWarrantMember us-gaap:CommonStockMember 2025-03-31 2025-03-31 0001601485 eltx:The2021PlanMember 2026-03-31 0001601485 eltx:The2022PlanMember 2026-03-31 0001601485 eltx:Inducement2024PlanMember 2026-01-01 2026-03-31 0001601485 2025-01-01 2025-12-31 0001601485 us-gaap:EmployeeStockOptionMember 2026-01-01 2026-03-31 0001601485 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-03-31 0001601485 us-gaap:RestrictedStockUnitsRSUMember 2025-12-31 0001601485 us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-03-31 0001601485 us-gaap:RestrictedStockUnitsRSUMember 2026-03-31 0001601485 us-gaap:ResearchAndDevelopmentExpenseMember 2026-01-01 2026-03-31 0001601485 us-gaap:ResearchAndDevelopmentExpenseMember 2025-01-01 2025-03-31 0001601485 us-gaap:GeneralAndAdministrativeExpenseMember 2026-01-01 2026-03-31 0001601485 us-gaap:GeneralAndAdministrativeExpenseMember 2025-01-01 2025-03-31 0001601485 us-gaap:EmployeeStockMember 2026-03-31 0001601485 eltx:PreFundedWarrantMember us-gaap:CommonStockMember 2025-01-31 0001601485 eltx:PreFundedWarrantMember eltx:JulyPublicOfferingMember 2025-01-31 0001601485 eltx:June2025WarrantsMember 2025-06-30 0001601485 eltx:ElicioWarrantsMember 2026-03-31 0001601485 eltx:ElicioWarrantsMember srt:WeightedAverageMember 2026-03-31 0001601485 eltx:ElicioWarrantsMember 2026-01-01 2026-03-31 0001601485 eltx:AngionWarrantsMember 2026-03-31 0001601485 eltx:AngionWarrantsMember srt:WeightedAverageMember 2026-03-31 0001601485 eltx:AngionWarrantsMember 2026-01-01 2026-03-31 0001601485 eltx:March2024PreFundedWarrantsMember 2026-03-31 0001601485 eltx:March2024PreFundedWarrantsMember srt:WeightedAverageMember 2026-03-31 0001601485 eltx:PreFundedWarrantMember 2026-03-31 0001601485 eltx:PreFundedWarrantMember srt:WeightedAverageMember 2026-03-31 0001601485 eltx:JulyCommonWarrantsMember 2026-03-31 0001601485 eltx:JulyCommonWarrantsMember srt:WeightedAverageMember 2026-03-31 0001601485 eltx:JulyCommonWarrantsMember 2026-01-01 2026-03-31 0001601485 eltx:JulyCommonWarrantOneMember 2026-03-31 0001601485 eltx:JulyCommonWarrantOneMember srt:WeightedAverageMember 2026-03-31 0001601485 eltx:JulyCommonWarrantOneMember 2026-01-01 2026-03-31 0001601485 eltx:January2025CommonWarrantsMember srt:WeightedAverageMember 2026-03-31 0001601485 eltx:January2025CommonWarrantsMember 2026-01-01 2026-03-31 0001601485 eltx:June2025CommonWarrantsMember 2026-03-31 0001601485 eltx:June2025CommonWarrantsMember srt:WeightedAverageMember 2026-03-31 0001601485 eltx:June2025CommonWarrantsMember 2026-01-01 2026-03-31 0001601485 srt:WeightedAverageMember 2026-03-31 0001601485 srt:MinimumMember 2026-01-01 2026-03-31 0001601485 srt:MaximumMember 2026-01-01 2026-03-31 0001601485 eltx:UniversityMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2016-01-31 0001601485 eltx:UniversityMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2026-01-01 2026-03-31 0001601485 us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2026-01-01 2026-03-31 0001601485 us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember eltx:UniversityMember srt:ScenarioForecastMember 2026-12-31 0001601485 eltx:BostonMassachusettsMember 2022-02-01 2022-02-28 0001601485 eltx:BostonMassachusettsMember 2022-02-28 0001601485 2023-06-01 2023-06-30 0001601485 eltx:SeniorSecuredConvertiblePromissoryNoteMember srt:MaximumMember 2025-06-30 0001601485 eltx:SeniorSecuredConvertiblePromissoryNoteMember 2026-03-31 0001601485 us-gaap:DebtInstrumentRedemptionPeriodOneMember 2025-06-01 2025-06-30 0001601485 us-gaap:DebtInstrumentRedemptionPeriodTwoMember 2025-06-01 2025-06-30 0001601485 us-gaap:DebtInstrumentRedemptionPeriodThreeMember 2025-06-01 2025-06-30 0001601485 eltx:GKCCMember us-gaap:CommonStockMember 2025-06-30 0001601485 eltx:SeniorSecuredConvertiblePromissoryNoteMember 2026-01-01 2026-03-31 0001601485 us-gaap:EmployeeStockOptionMember 2026-01-01 2026-03-31 0001601485 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-03-31 0001601485 us-gaap:WarrantMember 2026-01-01 2026-03-31 0001601485 us-gaap:WarrantMember 2025-01-01 2025-03-31 0001601485 us-gaap:RestrictedStockMember 2026-01-01 2026-03-31 0001601485 us-gaap:RestrictedStockMember 2025-01-01 2025-03-31 0001601485 eltx:JulyPreFundedWarrantsAndJulyCommonWarrantsMember eltx:JayVenkatesanAndTrustsAffiliatedWithJayVenkatesanMember eltx:PurchaseOfWarrantsMember eltx:July2024PublicOfferingMember 2026-01-01 2026-03-31 0001601485 eltx:JulyPreFundedWarrantsAndJulyCommonWarrantsMember eltx:JayVenkatesanAndTrustsAffiliatedWithJayVenkatesanMember eltx:PurchaseOfWarrantsMember eltx:July2024PublicOfferingMember 2026-03-31 0001601485 eltx:ClinicalTrailMember eltx:ReportableSegmentMember 2026-01-01 2026-03-31 0001601485 eltx:ClinicalTrailMember eltx:ReportableSegmentMember 2025-01-01 2025-03-31 0001601485 eltx:EmployeeRelatedReasearchAndDevelopmentMember eltx:ReportableSegmentMember 2026-01-01 2026-03-31 0001601485 eltx:EmployeeRelatedReasearchAndDevelopmentMember eltx:ReportableSegmentMember 2025-01-01 2025-03-31 0001601485 eltx:TranslationalMedicineAndCMCMember eltx:ReportableSegmentMember 2026-01-01 2026-03-31 0001601485 eltx:TranslationalMedicineAndCMCMember eltx:ReportableSegmentMember 2025-01-01 2025-03-31 0001601485 eltx:OtherMember eltx:ReportableSegmentMember 2026-01-01 2026-03-31 0001601485 eltx:OtherMember eltx:ReportableSegmentMember 2025-01-01 2025-03-31 0001601485 eltx:ReportableSegmentMember 2026-01-01 2026-03-31 0001601485 eltx:ReportableSegmentMember 2025-01-01 2025-03-31 0001601485 eltx:ReportableSegmentMember 2026-03-31 0001601485 eltx:ReportableSegmentMember 2025-03-31 0001601485 eltx:A2026ATMProgramMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2026-04-01 2026-05-08 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.
    • These forward-looking statements include, but are not limited to, statements about: • our financial condition, including our ability to obtain the funding necessary to advance the development of ELI-002 7P and any other current or future product candidates, our ability to continue as a going concern and our cash runway; • the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results; • our ability to utilize our platform to develop a pipeline of product candidates to address unmet needs in oncology and other disease areas; • the timing, progress and results of clinical trials for ELI-002 7P, and other current or future product candidates we may develop, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the studies or trials will become available, and the timing, progress and results of our research and development programs; • the timing, scope and likelihood of regulatory filings and approvals, including timing of Investigational New Drug applications and U.S.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2026-03-31
    Q4 2025 · Quarter highlights

    Operating income -$10.6M.

    Revenue—
    Operating income-$10.6M
    Net income-$11.8M
    Free cash flow—
    EPS—
    Operating cash flow-$11.6M
    Financials
    Income statement
    Revenue—
    Gross profit—
    Operating income-$10.6M
    Net income-$11.8M
    Balance sheet
    Total assets$22.7M
    Total liabilities$24.1M
    Total equity-$1.4M
    Cash & equivalents$14.9M
    Long-term debt$9.5M
    Cash flow
    Operating cash flow-$11.6M
    CapEx—
    Free cash flow—
    SBC$868.0k
    Highlights
    • ▍Operating income -$10.6M

    Valuation FY

    Market price
    $2,85
    Market cap
    $58.6M
    Enterprise valueⓘ
    $53.2M
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    -$1.4M
    Net cashⓘ
    $5.5M
    Current ratioⓘ
    2.2
    Debt / equityⓘ
    -6.6
    ROAⓘ
    -52.1%
    ROEⓘ
    8.2%
    Cash conversionⓘ
    98.0%
    CapEx / revenueⓘ
    —
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    -2.3%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    -2,01
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    4
    Other metrics
    Revenue
    —
    no estimate
    Segment revenue
    —
    no estimate
    Margin
    —
    no estimate
    Segment margin
    —
    no estimate
    as of 2026-07-03 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPS—no estimate—no estimate-2,01
    Revenue—no estimate—no estimate0 USD
    Operating income—no estimate—no estimate-42,1M USD
    Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution4 analysts
    Strong buy1
    Buy2
    Hold1
    Sell0
    Strong sell0
    12-month price target$20,00 · Median $23,00
    Low $10,00High $27,00
    Operating income · consensus-42,1M USD
    EPS surprise
    −28,6 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$10,00
    Mean$20,00
    Median$23,00
    High$27,00
    Spot$2,85
    +601.8 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskMedium
    Liquidity riskHigh
    Filing-based flags
    • Filings reference going-concern or substantial-doubt language.
    • Source documents mention dilution or offering risk.

    Benchmarks vs cohort

    ROE822,8 %Best in class
    D/E-6,59Best in class
    Cash Conv0,98Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net acquired 652 490 sh1 exercises · 8 grants4 insiders
    • Haqq ChristopherSee Remarks · Stock Option (Right to Buy) → Common StockAcquired 64 643 @ $3,20grant · 2026-07-16
    • Shah PreetamSee Remarks · Stock Option (Right to Buy) → Common StockAcquired 60 833 @ $3,20grant · 2026-07-16
    • Connelly RobertDirector, CEO, President and Director · Stock Option (Right to Buy) → Common StockAcquired 186 944 @ $3,20grant · 2026-07-16
    • DeMuth PeterChief Scientific Officer · Stock Option (Right to Buy) → Common StockAcquired 52 832 @ $3,20grant · 2026-07-16
    • Shah PreetamSee Remarks · Stock Option (Right to Buy) → Common StockAcquired 47 900 @ $8,10grant · 2026-02-02
    • Connelly RobertDirector, CEO, President and Director · Stock Option (Right to Buy) → Common StockAcquired 147 200 @ $8,10grant · 2026-02-02
    • Haqq ChristopherSee Remarks · Stock Option (Right to Buy) → Common StockAcquired 50 900 @ $8,10grant · 2026-02-02
    • DeMuth PeterChief Scientific Officer · Stock Option (Right to Buy) → Common StockAcquired 41 600 @ $8,10grant · 2026-02-02
    • DeMuth PeterChief Scientific Officer · Stock Option (Right to Buy) → Common StockDisposed 362 @ $4,41exercise · 2025-12-09

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Regulatory filings
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    • Reference data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Return On Assets
      net_income / total_assets
    • Enterprise Value
      market_cap - net_cash
    • Market Cap
      market_price * shares_outstanding_diluted
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Elicio Therapeutics, Inc. company facts · 2026-07-03
    • Elicio Therapeutics, Inc. 10-Q 2026-05-11 · 2026-07-03
    • Elicio Therapeutics, Inc. 10-K 2026-03-12 · 2026-07-03
    • Elicio Therapeutics, Inc. 10-Q 2025-11-13 · 2026-07-03
    • Elicio Therapeutics, Inc. 10-Q 2025-08-07 · 2026-07-03
    • 8-K (sec_8k_material) on ELTX · 2026-07-03
    • Elicio Therapeutics Inc Market data — analyst estimates · 2026-07-03

    Ownership & reference

    Top holders

    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$1M
    • Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$1M
    • Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$1M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$4M
    • Raymond James & Associates, Inc.Brokerage Firms · as of 2026-03-310,00 %$0M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$0M
    • State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$1M
    • BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$0M

    Insider activity

    Mixed / flat0 buys · 0 sellsnet $04 insiders · last 365d
    • Haqq ChristopherSee Remarks · Common StockOther 25 400 · 2026-02-02
    • DeMuth PeterChief Scientific Officer · Common StockOther 20 800 · 2026-02-02
    • Connelly RobertDirector, CEO, President and Director · Common StockOther 73 600 · 2026-02-02
    • Shah PreetamSee Remarks · Common StockOther 24 000 · 2026-02-02
    • DeMuth PeterChief Scientific Officer · Common StockOther 362 @ $4,41$2K · 2025-12-09

    Short positioning

    1.9Mshares short+8.2% vs prior
    1.11days to cover
    72.8%short of daily vol
    31.2Kfails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    ELTXCanonical
    Nasdaq · USD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskMedium
    Liquidity riskHigh
    Filings reference going-concern or substantial-doubt language.
    Source documents mention dilution or offering risk.

    Evidence & claims

    From filings & derived data
    • EPS (basic) (annual): USD-PER-SHARES -3Unknown
    • Total liabilities (annual): USD 24.23MUnknown
    • Shareholders' equity (annual): USD 1.64MUnknown
    • Total assets (annual): USD 25.86MUnknown
    • Net income (annual): USD -39.57MUnknown
    • Pre-tax income (annual): USD -39.57MUnknown
    • Capex (annual): USD 16KUnknown
    • R&D expense (annual): USD 24.9MUnknown
    • EPS (diluted) (annual): USD-PER-SHARES -3Unknown
    • Cash & equivalents (annual): USD 18.56MUnknown
    • Current assets (annual): USD 19.31MUnknown
    • Long-term debt (annual): USD 10MUnknown
    • Current liabilities (annual): USD 8.11MUnknown
    • Operating cash flow (annual): USD -36.95MUnknown
    • Operating income (annual): USD -37.71MUnknown
    • Shares outstanding (annual): 17.8MUnknown
    • Total assets (annual): USD 28.18MUnknown
    • Cash & equivalents (annual): USD 17.62MUnknown
    • Shares outstanding (annual): 11.03MUnknown
    • Operating cash flow (annual): USD -37.07MUnknown
    • R&D expense (annual): USD 33.66MUnknown
    • EPS (diluted) (annual): USD-PER-SHARES -4Unknown
    • EPS (basic) (annual): USD-PER-SHARES -4Unknown
    • Current assets (annual): USD 20.69MUnknown
    Showing 24 of 32 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-07-16INSIDERDeMuth Peter acquired 52.8k sh Stock Option (Right to Buy) — Chief Scientific Officer
    2026-07-16INSIDERShah Preetam acquired 60.8k sh Stock Option (Right to Buy) — See Remarks
    2026-07-16INSIDERHaqq Christopher acquired 64.6k sh Stock Option (Right to Buy) — See Remarks
    2026-07-16INSIDERConnelly Robert acquired 186.9k sh Stock Option (Right to Buy) — Director, CEO, President and Director
    2026-07-03 04:32 UTCFILINGMaterial 8-K
    2026-06-17FILING8-K filing →
    2026-06-15FILING8-K filing →
    2026-05-11FILING10-Q filing →
    2026-05-11FILING8-K filing →
    2026-03-31EARNINGSQuarterly results — Q4 2025 Net USD -11.8M
    2026-03-16FILING8-K filing →
    2026-03-16FILING424B5 filing →
    2026-03-12FILING10-K filing →
    2026-03-12FILING8-K filing →
    2026-02-02 00:00 UTCINSIDER8 insider transactions — 2026-02 4 derivative
    2026-02-02INSIDERHaqq Christopher transacted 25.4k sh — See Remarks
    2026-02-02INSIDERDeMuth Peter transacted 20.8k sh — Chief Scientific Officer
    2026-02-02INSIDERConnelly Robert transacted 73.6k sh — Director, CEO, President and Director
    2026-02-02INSIDERShah Preetam transacted 24.0k sh — See Remarks
    2026-02-02INSIDERHaqq Christopher acquired 50.9k sh Stock Option (Right to Buy) — See Remarks
    2026-02-02INSIDERDeMuth Peter acquired 41.6k sh Stock Option (Right to Buy) — Chief Scientific Officer
    2026-02-02INSIDERShah Preetam acquired 47.9k sh Stock Option (Right to Buy) — See Remarks
    2026-02-02INSIDERConnelly Robert acquired 147.2k sh Stock Option (Right to Buy) — Director, CEO, President and Director
    2025-12-31EARNINGSQuarterly results — Q3 2025
    2025-12-31EARNINGSAnnual results — FY 2025 Net USD -39.6M
    2025-12-09 00:00 UTCINSIDER2 insider transactions — 2025-12 1 derivative
    2025-12-09INSIDERDeMuth Peter transacted 362 sh — Chief Scientific Officer ~$2k
    2025-12-09INSIDERDeMuth Peter disposed of 362 sh Stock Option (Right to Buy) — Chief Scientific Officer
    2025-11-13FILING10-Q filing →
    2025-11-13FILING8-K filing →
    2025-09-30EARNINGSQuarterly results — Q2 2025 Net USD -31.9M
    2025-09-17FILING8-K filing →
    2025-08-12FILING8-K filing →
    2025-06-30EARNINGSQuarterly results — Q1 2025 Net USD -21.8M
    2025-06-03 00:00 UTCINSIDER1 insider transaction — 2025-06 1 derivative
    2025-05-19 00:00 UTCINSIDER7 insider transactions — 2025-05 7 derivative
    2025-04-15 00:00 UTCINSIDER1 insider transaction — 2025-04 1 derivative
    2025-03-05 00:00 UTCINSIDER2 insider transactions — 2025-03 · net buy $20.3M 1 derivative
    2025-02-03 00:00 UTCINSIDER3 insider transactions — 2025-02 3 derivative
    Showing the 40 most recent of 43 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data Premium coverage